Extraintestinal manifestations (EIM) are common complications of inflammatory bowel disease (IBD) associated with morbidity and reduced quality of life (QOL). The aim of this study was to identify and validate predictors for EIM in children with IBD.
The medical records of children with IBD were retrospectively reviewed, and EIM present before diagnosis and those detected during follow-up, were recorded.
One-hundred children were included, and their median age (interquartile range) was 13.9 (11.9–15.2) years. Forty-six (46%) children had EIM, including 10 (10%) whose EIM was present before diagnosis and 36 (36%) during follow-up. The most common EIMs were aphthous stomatitis (18%), arthralgia (14%), dermatologic manifestations (8%), and arthritis (6%). A body mass index in the lower or upper quartile (hazard ratio [HR] 9.30 and 23.71, respectively, p < 0.001), moderate-to-severe disease activity (HR 4.43, p < 0.001), extensive Crohn’s disease (HR 3.43, p = 0.025), lower hemoglobin level (HR 2.29, p < 0.001), lower albumin level (HR 2.86, p = 0.029), and higher C-reactive protein level (HR 1.04, p < 0.001) at diagnosis were identified as risk factors for EIM during follow-up.
Identification of risk factors at IBD diagnosis may help healthcare providers to predict EIM in children with IBD and to improve their management for lessening morbidity and enhancing QOL.
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, et al. Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort Study. Inflamm Bowel Dis. 2017;23:1174–81.
Isene R1, Bernklev T, Høie O, Munkholm P, Tsianos E, Stockbrügger R, et al. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: Results from a prospective, population-based European inception cohort. Scand J Gastroenterol. 2015;50:300–5.
Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease: Prevalence, presentation, and anti-TNF treatment. J Pedia Gastroenterol Nutr. 2017;65:200–6.
Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110–9.
Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81:580–5.
Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:1424–9.
Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol. 1985;80:615–20.
Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585–95.
Vavricka SR, Gantenbein C, Spoerri M, Spoerri M, Prinz Vavricka M, Navarini AA, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015;21:1794–1800.
Karmiris K, Avgerinos A, Tavernaraki A, Zeglinas C, Karatzas P, Koukouratos T, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. J Crohns Colitis. 2016;10:429–36.
Severs M, Spekhorst LM, Mangen MJ, Dijkstra G, Löwenberg M, Hoentjen F, et al. Sex-related differences in patients with inflammatory bowel disease: Results of 2 prospective cohort studies. Inflamm Bowel Dis. 2018;24:1298–306.
Vegh Z, Kurti Z, Gonczi L, Golovics PA, Lovasz BD, Szita I, et al. Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease. Scand J Gastroenterol. 2016;51:848–54.
Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40(Suppl. 2):S253–9.
Singla MB, Eickhoff C, Betteridge J. Extraintestinal manifestations are common in obese patients with Crohn’s disease. Inflamm Bowel Dis. 2017;23:1637–42.
Satsangi J, Grootscholten C, Holt H, Jewell DP. Clinical patterns of familial inflammatory bowel disease. Gut. 1996;38:738–41.
Herzog D, Fournier N, Buehr P, Rueger V, Koller R, Heyland K, et al. Age at disease onset of inflammatory bowel disease is associated with later extraintestinal manifestations and complications. Eur J Gastroenterol Hepatol. 2018;30:598–607.
Hata K, Ishii H, Anzai H. Preoperative extraintestinal manifestations associated with chronic pouchitis in Japanese patients with ulcerative colitis after ileal pouch-anal anastomosis: a retrospective study. Inflamm Bowel Dis. 2017;23:1019–24.
Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci. 1999;44:1–13.
Monsén U, Sorstad J, Hellers G, Johansson C. Extracolonic diagnoses in ulcerative colitis: An epidemiological study. Am J Gastroenterol. 1990;85:711–6.
Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pedia Gastroenterol Nutr. 2014;58:795–806.
Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–21.
Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, et al. Appraisal of the pediatric Crohn’s disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol. 2010;105:2085–92.
Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133:423–32.
Jose FA, Garnett EA, Vittinghoff E, Ferry GD, Winter HS, Baldassano RN, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:63–68.
Guariso G, Gasparetto M, Visonà Dalla Pozza L, D’Incà R, Zancan L, Sturniolo G, et al. Inflammatory bowel disease developing in paediatric and adult age. J Pedia Gastroenterol Nutr. 2010;51:698–707.
Dotson JL, Hyams JS, Markowitz J, LeLeiko NS, Mack DR, Evans JS, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pedia Gastroenterol Nutr. 2010;51:140–5.
Stawarski A, Iwanczak B, Krzesiek E, Iwańczak F. Intestinal complications and extraintestinal manifestations in children with inflammatory bowel disease. Pol Merkur Lek. 2006;20:22–5.
Corica D, Romano C. Renal involvement in inflammatory bowel diseases. J Crohns Colitis. 2016;10:226–35.
Yerushalmy-Feler A, Ben-Tov A, Weintraub Y, Amir A, Galai T, Moran-Lev H, et al. High and low body mass index may predict severe disease course in children with inflammatory bowel disease. Scand J Gastroenterol. 2018;53:708–13.
Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor alpha in human obesity and insulin resistance. J Clin Investig. 1995;95:2409–15.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Cohen, S., Padlipsky, J. & Yerushalmy-Feler, A. Risk factors associated with extraintestinal manifestations in children with inflammatory bowel disease. Eur J Clin Nutr 74, 691–697 (2020). https://doi.org/10.1038/s41430-019-0490-1
Increasing rate of a positive family history of inflammatory bowel disease (IBD) in pediatric IBD patients
European Journal of Pediatrics (2021)